Clinical trial to evaluate the effects of chemotherapy with anthracycline, after radiotherapy, in a group of pediatric and young adult patients with glioblastoma

Prior treatment

• Perform a 1st line chemotherapy cycle at the same time as the start of the study

Other illness

• Evidence of any other serious illness or condition that is a contraindication to study therapy (e.g. severe mental retardation, severe cerebral palsy, severe congenital syndromes, heart disease)

Other

• Simultaneous participation in other research projects
• State of pregnancy or breastfeeding
• Use of inadequate contraceptive methods

• Patients with histological-molecular diagnosis according to WHO 2016 classification: Glioblastoma IDH-wildtype (9440/3), giant cell glioblastoma (9441/3), gliosarcoma (9442/3), epithelioid glioblastoma (9440/3), IDH glioblastoma mutant (9445/3), NOS glioblastoma (9440/3), diffuse astrocytoma (9400/3), diffuse midline glioma H3 K27M mutated, including multifocal, metastatic, or previously untreated gliomatosis cerebri contextes (with chemo and radiotherapy) or treated only surgically (total, almost partial, partial, biopsy).
• Males and females between the ages of 3 and 30
• Life expectancy > or = 12 months
• Karnofsky/Lansky > o = 80%
• Adequate haematological function: Absolute white blood cell count >= 2.0 x 10^9 /l; Hemoglobin >= 10 g/dl; Platelet count >= 50 x 109/l
• Adequate liver function: Total bilirubin <= 2.5 x ULN; ALT / AST <= 5.0 x ULN
• Adequate renal function: Serum creatinine <= 1.5 x ULN
• Written informed consent from the patient, parents or legal guardians
• Patient availability during treatment and ability to comply with the protocol